Journal
ESC HEART FAILURE
Volume 10, Issue 2, Pages 753-761Publisher
WILEY PERIODICALS, INC
DOI: 10.1002/ehf2.14153
Keywords
Biomarkers; Heart failure; microRNA; Therapy
Categories
Ask authors/readers for more resources
Heart failure is a significant health issue with a high burden on both society and the economy. Recent research has shown that microRNAs play an important role in the development and prognosis of heart failure, serving as biomarkers for diagnosis and prognosis. Exploration of microRNAs as potential therapeutic targets is also ongoing.
Heart failure is a leading cause of morbidity and mortality, with relevant social and economic burden on global healthcare system. Although the development of novel diagnostic tools and the advance in therapies have deeply influenced the diagnosis and treatment of this disease, improving both prognosis and life expectancy of patients, hospitalization is still high, and mortality remains considerable. MicroRNAs are small endogenous RNA molecules that post-transcriptionally regulate gene expression in both physiological and pathological processes. In recent years, microRNA have arisen as attractive therapeutic targets in the treatment of a wide spectrum of pathologies, including heart failure. In cardiac pathology, deregulation of microRNAs expression and function is associated to adverse outcome and heart failure progression. Circulating levels of specific microRNAs have emerged as useful biomarkers for the diagnosis of heart failure or as prognostic indicators. In the present review, we summarize the state of current research on the role of miRNAs as biomarkers for diagnosis and prognosis in patients with heart failure and their use as potential therapeutic targets for this condition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available